Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines

被引：156

作者：

Barrett, P. Noel ^{[1
]}

Mundt, Wolfgang ^{[2
]}

Kistner, Otfried ^{[1
]}

Howard, M. Keith ^{[1
]}

机构：

[1] Baxter BioSci, Biomed Res Ctr, A-2304 Orth, Austria

[2] IZD Tower, Baxter BioSci, A-1220 Vienna, Austria

来源：

EXPERT REVIEW OF VACCINES | 2009年 / 8卷 / 05期

关键词：

continuous cell line; emerging virus disease; influenza; rotavirus; smallpox; Vero; viral vaccine; JAPANESE ENCEPHALITIS VACCINE; NILE-VIRUS ISOLATION; ATTENUATED VACCINE; INFLUENZA-VIRUS; PROTECTIVE EFFICACY; CLINICAL-TRIALS; EGG-ADAPTATION; CHIMERIVAX-JE; DENGUE; LIVE;

D O I：

10.1586/ERV.09.19

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The development of cell culture systems for virus propagation has led to major advances in virus vaccine development. Primary and diploid cell culture systems are now being replaced by the use of continuous cell lines (CCLs). These substrates are gaining increasing acceptance from regulatory authorities as improved screening technologies remove fears regarding their potential oncogenic properties. The Vero cell line is the most widely accepted CCL by regulatory authorities and has been used for over 30 years for the production of polio and rabies virus vaccines. The recent licensure of a Vero cell-derived live virus vaccine (ACAM2000, smallpox vaccine) has coincided with an explosion in the development of a range of new viral vaccines, ranging from live-attenuated pediatric vaccines against rotavirus infections to inactivated whole-virus vaccines against H5N1 pandemic influenza. These developments have illustrated the value of this cell culture platform in the rapid development of vaccines against a range of virus diseases.

引用

页码：607 / 618

页数：12

共 91 条

[21]

*EUR PHARM, 2005, CELL SUBSTR PROD VAC, P50203

[22]

Furesz J, 1989, Dev Biol Stand, V70, P233

[23] Dengue and dengue hemorrhagic fever [J].

Gubler, DJ .

CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (03) :480-+

[24] Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates [J].

Guirakhoo, F ;

Pugachev, K ;

Zhang, Z ;

Myers, G ;

Levenbook, I ;

Draper, K ;

Lang, J ;

Ocran, S ;

Mitchell, F ;

Parsons, M ;

Brown, N ;

Brandler, S ;

Fournier, C ;

Barrere, B ;

Rizvi, F ;

Travassos, A ;

Nichols, R ;

Trent, D ;

Monath, T .

JOURNAL OF VIROLOGY, 2004, 78 (09) :4761-4775

[25] Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis [J].

Guirakhoo, F ;

Zhang, ZX ;

Chambers, TJ ;

Delagrave, S ;

Arroyo, J ;

Barrett, ADT ;

Monath, TP .

VIROLOGY, 1999, 257 (02) :363-372

[26] EGG FLUIDS AND CELLS OF THE CHORIOALLANTOIC MEMBRANE OF EMBRYONATED CHICKEN EGGS CAN SELECT DIFFERENT VARIANTS OF INFLUENZA-A (H3N2) VIRUSES [J].

HARDY, CT ;

YOUNG, SA ;

WEBSTER, RG ;

NAEVE, CW ;

OWENS, RJ .

VIROLOGY, 1995, 211 (01) :302-306

[27] SERIAL CULTIVATION OF HUMAN DIPLOID CELL STRAINS [J].

HAYFLICK, L ;

MOORHEAD, PS .

EXPERIMENTAL CELL RESEARCH, 1961, 25 (03) :585-+

[28] Chikungunya infection in travelers [J].

Hochedez, Patrick ;

Jaureguiberry, Stephane ;

Debruyne, Monique ;

Bossi, Philippe ;

Hausfater, Pierre ;

Brucker, Gilles ;

Bricaire, Francois ;

Caumes, Eric .

EMERGING INFECTIOUS DISEASES, 2006, 12 (10) :1565-1567

[29]

HORAUD F, 1992, DEV BIOLOGICALS, V76, P43

[30] Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines [J].

Howard, M. Keith ;

Kistner, Offried ;

Barrett, P. Noel .

BIOLOGICAL CHEMISTRY, 2008, 389 (05) :569-577

← 1 2 3 4 5 6 7 8 9 10 →